To begin investigating the hypothesized synergy between inhibition of WEE1 and KRASG12C, we assembled a panel of NSCLC cell lines with varying levels of sensitivity to both azenosertib and the KRASG12C inhibitors sotorasib and adagrasib. The gene discussed is WEE1; the disease is non-small cell lung carcinoma.